Study of PWT33597 Mesylate in Subjects With Advanced Malignancies
NCT01407380
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
22
Enrollment
INDUSTRY
Sponsor class
Conditions
Malignancies
Interventions
DRUG:
PWT33597 mesylate
Sponsor
Pathway Therapeutics, Inc.